Risperdal
Schizophrenia, Paranoid
Hospital Authority, Hong KongN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Schizophrenia, Paranoid cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Asenapine Organon and Co | Phase 3 | BB |
Long-Acting Risperidone Microspheres Hospital Authority, Hong Kong | N/A | D |
Same molecule, other indications
Risperdal is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →